Cargando…

HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia

Mostrar otras versiones (1)

BACKGROUND: The aim of the present study was to investigate whether changes in the tissue expression of human epididymis-specific protein 4 (HE4) could predict therapy resistance and relapse after progestin hormone therapy for medium- and low-risk endometrial hyperplasia. METHODS: Endometrial biopsi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ørbo, Anne, Arnes, Marit, Lyså, Lena Myreng, Borgfelt, Christer, Straume, Bjørn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5023780/ https://www.ncbi.nlm.nih.gov/pubmed/27537387 http://dx.doi.org/10.1038/bjc.2016.247

Ejemplares similares

HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia
por: Ørbo, Anne, et al.
Publicado: (2016)

Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel‐impregnated intrauterine system or oral progestogens
por: Ørbo, A, et al.
Publicado: (2015)

Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial*
por: Ørbo, A, et al.
Publicado: (2014)

Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients
por: Bignotti, E, et al.
Publicado: (2011)

Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer
por: Nalwoga, H, et al.
Publicado: (2010)

Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia
por: Giskeødegård, Guro F, et al.
Publicado: (2015)

Tetraspanin CD151 is a novel prognostic marker in poor outcome endometrial cancer
por: Voss, M A, et al.
Publicado: (2011)

Individualised proteome profiling of human endometrial tumours improves detection of new prognostic markers
por: Attarha, S, et al.
Publicado: (2013)

Progestin Resistance and Corresponding Management of Abnormal Endometrial Hyperplasia and Endometrial Carcinoma
por: Lv, Mu, et al.
Publicado: (2022)

Strong expression of ID1 protein is associated with decreased survival, increased expression of ephrin-A1/EPHA2, and reduced thrombospondin-1 in malignant melanoma
por: Straume, O, et al.
Publicado: (2005)

Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas
por: Bignotti, E, et al.
Publicado: (2008)

Prognostic importance of CDK4/6-specific activity as a predictive marker for recurrence in patients with endometrial cancer, with or without adjuvant chemotherapy
por: Ikeda, Yuji, et al.
Publicado: (2015)

Loss of the cell polarity determinant human Discs-large is a novel molecular marker of nodal involvement and poor prognosis in endometrial cancer
por: Sugihara, Takeru, et al.
Publicado: (2016)

Angiogenesis is associated with the onset of hyperplasia in human ductal breast disease
por: Bluff, J E, et al.
Publicado: (2009)

Androgen receptors are acquired by healthy postmenopausal endometrial epithelium and their subsequent loss in endometrial cancer is associated with poor survival
por: Kamal, A M, et al.
Publicado: (2016)

Infrared spectroscopy with multivariate analysis to interrogate endometrial tissue: a novel and objective diagnostic approach
por: Taylor, S E, et al.
Publicado: (2011)

Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts
por: Huhtinen, K, et al.
Publicado: (2009)

Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis
por: Shao, Fengping, et al.
Publicado: (2023)

HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm
por: Van Gorp, T, et al.
Publicado: (2011)

Progestin Intrauterine Devices and Metformin: Endometrial Hyperplasia and Early Stage Endometrial Cancer Medical Management
por: Nwanodi, Oroma
Publicado: (2017)

Impact of genomic stability on protein expression in endometrioid endometrial cancer
por: Lomnytska, M I, et al.
Publicado: (2012)

A clinically applicable molecular-based classification for endometrial cancers
por: Talhouk, A, et al.
Publicado: (2015)

Differential tissue-specific protein markers of vaginal carcinoma
por: Hellman, K, et al.
Publicado: (2009)

Expression of N-acetylglucosaminyltransferase V in endometrial cancer correlates with poor prognosis
por: Yamamoto, E, et al.
Publicado: (2007)

The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas
por: Shoji, K, et al.
Publicado: (2009)

L1CAM expression in endometrial carcinomas: an ENITEC collaboration study
por: van der Putten, Louis JM, et al.
Publicado: (2016)

Identification of Genes and Pathways Differentially Expressed in Progestin Responsive Endometrial Cancer and Hyperplasia
por: Gertz, Jay, et al.
Publicado: (2021)

Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer
por: Ino, K, et al.
Publicado: (2006)

Expression of HER-2 affects patient survival and paclitaxel sensitivity in endometrial cancer
por: Mori, N, et al.
Publicado: (2010)

Preoperative neutrophil:lymphocyte and platelet:lymphocyte ratios predict endometrial cancer survival
por: Cummings, M, et al.
Publicado: (2015)

Similar protein expression profiles of ovarian and endometrial high-grade serous carcinomas
por: Hiramatsu, Kosuke, et al.
Publicado: (2016)

Prognostic significance of gamma-glutamyltransferase in patients with endometrial cancer: a multi-centre trial
por: Seebacher, V, et al.
Publicado: (2012)

pHH3 and survivin are co-expressed in high-risk endometrial cancer and are prognostic relevant
por: Brunner, A, et al.
Publicado: (2012)

Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters
por: Versluis, M A, et al.
Publicado: (2015)

Increased microvascular proliferation is negatively correlated to tumour blood flow and is associated with unfavourable outcome in endometrial carcinomas
por: Haldorsen, I S, et al.
Publicado: (2014)

Endosialin expression in soft tissue sarcoma as a potential marker of undifferentiated mesenchymal cells
por: Thway, Khin, et al.
Publicado: (2016)

Pair-Box (PAX8) protein-positive expression is associated with poor disease outcome in women with endometrial cancer
por: Mhawech-Fauceglia, P, et al.
Publicado: (2012)

Tamoxifen resistance in early breast cancer: statistical modelling of tissue markers to improve risk prediction
por: Baneshi, M R, et al.
Publicado: (2010)

Endocervical glandular neoplasia associated with lobular endocervical glandular hyperplasia is HPV-independent and correlates with carbonic anhydrase-IX expression: a Gynaecological Oncology Group Study
por: Liao, S Y, et al.
Publicado: (2013)

Associations between hepatocyte growth factor, c-Met, and basic fibroblast growth factor and survival in endometrial cancer patients
por: Felix, A S, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_a7eg4n7o1m49hdeb32dgt1fpop